Read inEnglishहिन्दीગુજરાતી
Money

Suven-Cohance Merger Approved by NCLT

In brief · AI summary The National Company Law Tribunal approved the merger of Suven Pharmaceuticals with Cohance Lifesciences on March 27, 2025, and the deal will take effect once all regulatory conditions are met. Approval from the Department of Pharmaceuticals is still required, with completion expected by Q1FY26. The combined company aims to reach $1 billion in revenue in five years and will focus on antibody drug conjugates, oligonucleotides, and small molecules.

By Deshwale Business Desk  ·   ·  1 min read
Suven-Cohance Merger Approved by NCLT

Amalgamation to Create a Diversified CDMO Leader

Suven Pharmaceuticals has received NCLT approval to merge with Cohance Lifesciences. The tribunal sanctioned the deal on March 27, 2025.

What’s Next?

The merger will take effect after meeting all regulatory conditions. Approval from the Department of Pharmaceuticals is still required. The process is expected to be completed by Q1FY26.

Growth and Expansion

The combined entity will focus on:

  • Antibody Drug Conjugates (ADCs)
  • Oligonucleotides
  • Small Molecules

This merger will boost Suven’s global capabilities and strengthen its CDMO and API+ business.

Future Prospects

Suven aims to reach $1 billion in revenue in five years. The merger will enhance scale, innovation, and operational efficiency. The pharma giant is now set to deliver high-impact solutions to global clients.

Liked this? Get one story a day on WhatsApp.
Join

Read next

Indian AgriTech Eyes Global Markets as SC Agrotech Explores ₹60 Crore US Partnership What Will People Be Drinking in 2027? Five Cocktail Trends to Watch The Subscription Trap: How Small Monthly Payments Are Eating Into Salaries